company background image
INVA

InnovivaNasdaqGS:INVA Stock Report

Market Cap

US$1.1b

7D

3.4%

1Y

50.7%

Updated

26 Sep, 2021

Data

Company Financials +
INVA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

INVA Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals.

Innoviva Competitors

Pfizer

NYSE:PFE

US$246.4b

Merck

NYSE:MRK

US$186.3b

Abbott Laboratories

NYSE:ABT

US$220.5b

Price History & Performance

Summary of all time highs, changes and price drops for Innoviva
Historical stock prices
Current Share PriceUS$16.18
52 Week HighUS$9.21
52 Week LowUS$16.73
Beta0.55
1 Month Change10.22%
3 Month Change20.66%
1 Year Change50.65%
3 Year Change6.17%
5 Year Change47.23%
Change since IPO-10.66%

Recent News & Updates

Shareholder Returns

INVAUS PharmaceuticalsUS Market
7D3.4%0.5%0.1%
1Y50.7%14.3%35.3%

Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 14.3% over the past year.

Return vs Market: INVA exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is INVA's price volatile compared to industry and market?
INVA volatility
INVA Beta0.55
Industry Beta0.64
Market Beta1

Stable Share Price: INVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: INVA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19965Pavel Raifeldhttps://www.inva.com

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

Innoviva Fundamentals Summary

How do Innoviva's earnings and revenue compare to its market cap?
INVA fundamental statistics
Market CapUS$1.12b
Earnings (TTM)US$265.19m
Revenue (TTM)US$365.49m

4.2x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INVA income statement (TTM)
RevenueUS$365.49m
Cost of RevenueUS$1.32m
Gross ProfitUS$364.18m
ExpensesUS$98.99m
EarningsUS$265.19m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)3.82
Gross Margin99.64%
Net Profit Margin72.56%
Debt/Equity Ratio99.0%

How did INVA perform over the long term?

See historical performance and comparison

Valuation

Is Innoviva undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: INVA ($16.18) is trading below our estimate of fair value ($151.11)

Significantly Below Fair Value: INVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: INVA is good value based on its PE Ratio (4.2x) compared to the US Pharmaceuticals industry average (22x).

PE vs Market: INVA is good value based on its PE Ratio (4.2x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INVA is overvalued based on its PB Ratio (3.4x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Innoviva forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-16.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if INVA's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if INVA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INVA's revenue is expected to decline over the next 3 years (-16.7% per year).

High Growth Revenue: INVA's revenue is forecast to decline over the next 3 years (-16.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: INVA's Return on Equity is forecast to be low in 3 years time (17.3%).


Past Performance

How has Innoviva performed over the past 5 years?

25.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INVA has a large one-off gain of $80.3M impacting its June 30 2021 financial results.

Growing Profit Margin: INVA's current net profit margins (72.6%) are lower than last year (76.2%).


Past Earnings Growth Analysis

Earnings Trend: INVA's earnings have grown significantly by 25% per year over the past 5 years.

Accelerating Growth: INVA's earnings growth over the past year (16.3%) is below its 5-year average (25% per year).

Earnings vs Industry: INVA earnings growth over the past year (16.3%) underperformed the Pharmaceuticals industry 17.5%.


Return on Equity

High ROE: INVA's Return on Equity (85.6%) is considered outstanding.


Financial Health

How is Innoviva's financial position?


Financial Position Analysis

Short Term Liabilities: INVA's short term assets ($148.3M) exceed its short term liabilities ($5.4M).

Long Term Liabilities: INVA's short term assets ($148.3M) do not cover its long term liabilities ($390.0M).


Debt to Equity History and Analysis

Debt Level: INVA's debt to equity ratio (99%) is considered high.

Reducing Debt: INVA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: INVA's debt is well covered by operating cash flow (84.2%).

Interest Coverage: INVA's interest payments on its debt are well covered by EBIT (18.7x coverage).


Balance Sheet


Dividend

What is Innoviva current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: INVA is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average board tenure


CEO

Pavel Raifeld (37 yo)

1.33yrs

Tenure

US$1,943,968

Compensation

Mr. Pavel Raifeld, CFA, serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive with a strong background in strategy, business development and corporate fi...


CEO Compensation Analysis

Compensation vs Market: Pavel's total compensation ($USD1.94M) is about average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Insufficient data to compare Pavel's compensation with company performance.


Board Members

Experienced Board: INVA's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: INVA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Innoviva, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Innoviva, Inc.
  • Ticker: INVA
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.124b
  • Shares outstanding: 69.49m
  • Website: https://www.inva.com

Number of Employees


Location

  • Innoviva, Inc.
  • 1350 Old Bayshore Highway
  • Suite 400
  • Burlingame
  • California
  • 94010
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:11
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.